182 related articles for article (PubMed ID: 11113645)
1. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25.
Van den Mooter G; Wuyts M; Blaton N; Busson R; Grobet P; Augustijns P; Kinget R
Eur J Pharm Sci; 2001 Jan; 12(3):261-9. PubMed ID: 11113645
[TBL] [Abstract][Full Text] [Related]
2. Investigation into Intermolecular Interactions and Phase Behavior of Binary and Ternary Amorphous Solid Dispersions of Ketoconazole.
Sarpal K; Tower CW; Munson EJ
Mol Pharm; 2020 Mar; 17(3):787-801. PubMed ID: 31860316
[TBL] [Abstract][Full Text] [Related]
3. Role of the Strength of Drug-Polymer Interactions on the Molecular Mobility and Crystallization Inhibition in Ketoconazole Solid Dispersions.
Mistry P; Mohapatra S; Gopinath T; Vogt FG; Suryanarayanan R
Mol Pharm; 2015 Sep; 12(9):3339-50. PubMed ID: 26070543
[TBL] [Abstract][Full Text] [Related]
4. Physicochemical characterization of hot melt extruded bicalutamide-polyvinylpyrrolidone solid dispersions.
Andrews GP; AbuDiak OA; Jones DS
J Pharm Sci; 2010 Mar; 99(3):1322-35. PubMed ID: 19798757
[TBL] [Abstract][Full Text] [Related]
5. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
6. The Influence of the Strength of Drug-Polymer Interactions on the Dissolution of Amorphous Solid Dispersions.
Amponsah-Efah KK; Mistry P; Eisenhart R; Suryanarayanan R
Mol Pharm; 2021 Jan; 18(1):174-186. PubMed ID: 33332132
[TBL] [Abstract][Full Text] [Related]
7. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone.
Tantishaiyakul V; Kaewnopparat N; Ingkatawornwong S
Int J Pharm; 1999 Apr; 181(2):143-51. PubMed ID: 10370210
[TBL] [Abstract][Full Text] [Related]
8. Miniaturized Measurement of Drug-Polymer Interactions via Viscosity Increase for Polymer Selection in Amorphous Solid Dispersions.
Auch C; Harms M; Golitsyn Y; Reichert D; Mäder K
Mol Pharm; 2019 May; 16(5):2214-2225. PubMed ID: 30920843
[TBL] [Abstract][Full Text] [Related]
9. Relating hydrogen-bonding interactions with the phase behavior of naproxen/PVP K 25 solid dispersions: evaluation of solution-cast and quench-cooled films.
Paudel A; Nies E; Van den Mooter G
Mol Pharm; 2012 Nov; 9(11):3301-17. PubMed ID: 23009610
[TBL] [Abstract][Full Text] [Related]
10. Amorphous drug-PVP dispersions: application of theoretical, thermal and spectroscopic analytical techniques to the study of a molecule with intermolecular bonds in both the crystalline and pure amorphous state.
Tobyn M; Brown J; Dennis AB; Fakes M; Gao Q; Gamble J; Khimyak YZ; McGeorge G; Patel C; Sinclair W; Timmins P; Yin S
J Pharm Sci; 2009 Sep; 98(9):3456-68. PubMed ID: 19603506
[TBL] [Abstract][Full Text] [Related]
11. Solid state properties of pure UC-781 and solid dispersions with polyvinylpyrrolidone (PVP K30).
Damian F; Blaton N; Desseyn H; Clou K; Augustijns P; Naesens L; Balzarini J; Kinget R; Van den Mooter G
J Pharm Pharmacol; 2001 Aug; 53(8):1109-16. PubMed ID: 11518020
[TBL] [Abstract][Full Text] [Related]
12. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture.
Rumondor AC; Marsac PJ; Stanford LA; Taylor LS
Mol Pharm; 2009; 6(5):1492-505. PubMed ID: 19634917
[TBL] [Abstract][Full Text] [Related]
13. Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64.
Weuts I; Kempen D; Decorte A; Verreck G; Peeters J; Brewster M; Van den Mooter G
Eur J Pharm Sci; 2005 Jun; 25(2-3):313-20. PubMed ID: 15911228
[TBL] [Abstract][Full Text] [Related]
14. Physicochemical characterization and dissolution study of solid dispersions of ketoconazole with nicotinamide.
Aggarwal AK; Jain S
Chem Pharm Bull (Tokyo); 2011; 59(5):629-38. PubMed ID: 21532202
[TBL] [Abstract][Full Text] [Related]
15. Development of fully amorphous dispersions of a low T(g) drug via co-spray drying with hydrophilic polymers.
Zhao M; Barker SA; Belton PS; McGregor C; Craig DQ
Eur J Pharm Biopharm; 2012 Nov; 82(3):572-9. PubMed ID: 22922419
[TBL] [Abstract][Full Text] [Related]
16. Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers.
Khougaz K; Clas SD
J Pharm Sci; 2000 Oct; 89(10):1325-34. PubMed ID: 10980507
[TBL] [Abstract][Full Text] [Related]
17. Influence of preparation methods on solid state supersaturation of amorphous solid dispersions: a case study with itraconazole and eudragit e100.
Janssens S; De Zeure A; Paudel A; Van Humbeeck J; Rombaut P; Van den Mooter G
Pharm Res; 2010 May; 27(5):775-85. PubMed ID: 20195707
[TBL] [Abstract][Full Text] [Related]
18. Solid dispersions of diflunisal-PVP: polymorphic and amorphous states of the drug.
Martínez-Ohárriz MC; Rodríguez-Espinosa C; Martín C; Goñi MM; Tros-Ilarduya MC; Sánchez M
Drug Dev Ind Pharm; 2002 Jul; 28(6):717-25. PubMed ID: 12149965
[TBL] [Abstract][Full Text] [Related]
19. Studies on aging piroxicam-polyvinylpyrrolidone solid dispersions.
Ingkatawornwong S; Kaewnopparat N; Tantishaiyakul V
Pharmazie; 2001 Mar; 56(3):227-30. PubMed ID: 11265589
[TBL] [Abstract][Full Text] [Related]
20. Molecular mobility-based estimation of the crystallization rates of amorphous nifedipine and phenobarbital in poly(vinylpyrrolidone) solid dispersions.
Aso Y; Yoshioka S; Kojima S
J Pharm Sci; 2004 Feb; 93(2):384-91. PubMed ID: 14705195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
